RxDoctor Payments Data

Annacecilia Peacher Holderied, MD

Obstetrics & Gynecology · Georgetown, SCNPI 1891053195

Payments from drug & device makers

$1,945in general payments, 2019–2025

Across 50 payments — averaging $38.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$733
  • Caldera Medical, Inc$411
  • AbbVie$272
  • Axonics, Inc.$143
  • Boston Scientific$120
  • Astellas Pharma US Inc$117
  • plus $149 from 3 others

What the payments were for

  • Food & beverage$1,945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,945 in reported general payments places this provider in the 70th percentile of 673 obstetrics & gynecology providers in South Carolina.

See all obstetrics & gynecology providers in South Carolina

Medicare billing

Part B allowed, 2024
$323,439
Medicare patients
551
Services billed
2,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron331$187,087
GemtesaVibegron74$58,176
Estradiol343$26,475
Trospium Chloride ErTrospium Chloride125$26,210
Mirabegron ErMirabegron44$21,212
Solifenacin Succinate324$10,889
Tolterodine Tartrate ErTolterodine Tartrate82$4,449
Fosfomycin Tromethamine29$3,850
NitrofurantoinNitrofurantoin Macrocrystal157$2,990
Trimethoprim110$2,812
Fesoterodine Fumarate ErFesoterodine Fumarate30$2,377
Trospium Chloride55$2,326
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst156$1,718
Clobetasol Propionate47$1,509
Clobetasol EmollientClobetasol Propionate/Emoll35$1,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$117$187,087331 claims
Sumitomo Pharma America, Inc.Gemtesa$93$58,17674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 673 obstetrics & gynecology providers in South Carolina.

Other obstetrics & gynecology in Georgetown

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →